Entrada Therapeutics, Inc. (TRDA) has 16 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 12 sales totalling $10.3M. Most recent filing: Sept. 9, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 9, 2026 filed Sept. 4, 2026 | MPM BIOVENTURES 2018, L.P. 10% Owner | −$1,905,768 | 259,837 | −6% | No | |
|
|
||||||
| Sept. 9, 2026 filed Sept. 4, 2026 | MPM BioVentures 2014, L.P. 10% Owner | −$1,905,768 | 259,837 | −6% | No | |
|
|
||||||
| Sept. 3, 2026 filed Sept. 1, 2026 | MPM BIOVENTURES 2018, L.P. 10% Owner | −$617,379 | 86,482 | −2% | No | |
|
|
||||||
| Sept. 3, 2026 filed Sept. 1, 2026 | MPM BioVentures 2014, L.P. 10% Owner | −$617,379 | 86,482 | −2% | No | |
|
|
||||||
| Sept. 3, 2026 filed Sept. 2, 2026 | Doshi Dipal CEO | $62,323 | 8,724 | −2% | No | |
|
|
||||||
Showing the 5 most recent of 16 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free